Recombinant Measles AIK-C Vaccine Strain Expressing Influenza HA Protein. 2020

Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
Laboratory of Viral Infection II, Kitasato Institute for Life Sciences, Tokyo 108-8641, Japan.

Recombinant measles AIK-C vaccine expressing the hemagglutinin (HA) protein of influenza A/Sapporo/107/2013(H1N1pdm) (MVAIK/PdmHA) was constructed. Measles particle agglutination (PA) and influenza hemagglutinin inhibition (HI) antibodies were induced in cotton rats immunized with MVAIK/PdmHA. Cotton rats immunized with two doses of the HA split vaccine were used as positive controls, and higher HI antibodies were detected 3 weeks after the first dose. Following the challenge of A/California/07/2009(H1N1pdm), higher viral loads (107 TCID50/g) were detected in the lung homogenates of cotton rats immunized with the empty vector (MVAIK) or control groups than those immunized with MVAIK/Pdm HA (103 TCID50/g) or the group immunized with HA split vaccine (105 TCID50/g). Histopathologically, destruction of the alveolar structure, swelling of broncho-epithelial cells, and thickening of the alveolar wall with infiltration of inflammatory cells and HA antigens were detected in lung tissues obtained from non-immunized rats and those immunized with the empty vector after the challenge, but not in those immunized with the HA spilt or MVAIK/PdmHA vaccine. Lower levels of IFN-α, IL-1β, and TNF-α mRNA, and higher levels of IFN-γ mRNA were found in the lung homogenates of the MVAIK/PdmHA group. Higher levels of IFN-γ mRNA were detected in spleen cell culture from the MVAIK/PdmHA group stimulated with UV-inactivated A/California/07/2009(H1N1pdm). In conclusion, the recombinant MVAIK vaccine expressing influenza HA protein induced protective immune responses in cotton rats.

UI MeSH Term Description Entries

Related Publications

Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
January 2016, Vaccine,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
January 2004, Vaccine,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
January 2016, PloS one,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
February 2011, Vaccine,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
February 2006, Vaccine,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
February 2006, Vaccine,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
June 1974, The Kitasato archives of experimental medicine,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
September 2001, The Journal of general virology,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
April 2013, Pediatrics international : official journal of the Japan Pediatric Society,
Takashi Ito, and Takuji Kumagai, and Yoshiaki Yamaji, and Akihito Sawada, and Tetsuo Nakayama
June 1974, The Kitasato archives of experimental medicine,
Copied contents to your clipboard!